The Global Health Body Sounds Concern Over Critical Shortage of Weight-Loss Injections
Less than a tenth of patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the World Health Organization as it issues its initial guidance on the therapies.
Given over a billion individuals worldwide currently living with obesity, it is urging increased and just availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our new guidance recognises that excess weight is a long-term condition that can be managed with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to broad access to the treatments that can assist patients in reducing substantial body mass, explains the agency.
GLP-1 Therapy Scarcity
Even in the present most favorable scenario, the supply of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The recommendation calls on governments and firms to expand access, through strategies like voluntary licensing.
Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in several countries in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so people eat less.
People usually begin shedding pounds after several weeks of starting on the once-weekly jabs.
Studies indicates people may regain a significant portion within a year of stopping the drug, when their usual hunger resume.
Being overweight or obese elevates your chance for experiencing diseases, including diabetes, heart disease, brain attack, and specific cancers.
Excess weight concerns people in all nations and was associated with millions of deaths worldwide in 2024, per the WHO.
